FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

FDA监管成分

该成分是FDA批准或监管的。未经有效处方购买可能违反联邦法律。请在您所在地区核实所有法律规定。

HCG

Human Chorionic Gonadotropin / Pregnyl / Novarel

Sexual Health

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) activity at the Leydig cells. It is FDA-approved for the treatment of hypogonadism, cryptorchidism in pediatric patients, and as a fertility treatment to induce ovulation. In clinical practice, it is widely used alongside testosterone replacement therapy to maintain testicular function and intratesticular testosterone production.

作用机制

Glycoprotein hormone that mimics luteinizing hormone (LH) action. In males, stimulates Leydig cells to produce testosterone. In females, triggers ovulation and supports corpus luteum progesterone production. Maintains testicular function during exogenous hormone use.

研究协议

仅供研究使用,非医疗建议。

Male research protocols use 250-500 IU 2-3 times weekly to maintain testicular function. Female protocols (fertility) use 5,000-10,000 IU to trigger ovulation. Intramuscular or subcutaneous injection.

研究笔记

Clinical Research Status

HCG holds longstanding FDA approval for multiple indications including male hypogonadism, prepubertal cryptorchidism, and female infertility (ovulation induction). It has been used clinically since the 1930s with an extensive safety database spanning decades. Compounded HCG was temporarily restricted by the FDA in 2020 under the Biologics Control Act, though branded pharmaceutical versions (Pregnyl, Novarel) remain available.

Key Published Findings

Studies demonstrate that HCG at doses of 500-1500 IU two to three times weekly maintains intratesticular testosterone levels and spermatogenesis during exogenous testosterone administration. Research confirms LH receptor activation by HCG stimulates both testosterone production and supports Sertoli cell function critical for sperm maturation. In fertility contexts, HCG triggers final oocyte maturation at doses of 5,000-10,000 IU as a surrogate LH surge.

Safety Profile

Common side effects include injection site pain, headache, and mood fluctuations related to hormonal changes. Prolonged use at high doses can cause Leydig cell desensitization, potentially reducing endogenous LH receptor sensitivity. Gynecomastia may occur due to downstream aromatization of increased testosterone, and rare cases of ovarian hyperstimulation syndrome occur in female fertility use.

Comparison to Related Compounds

Unlike gonadorelin which stimulates the pituitary to release LH, HCG acts directly at the gonadal level bypassing the hypothalamic-pituitary axis. This makes HCG effective even in patients with suppressed gonadotropin release from exogenous testosterone use. Compared to recombinant LH (Luveris), HCG has a longer half-life of approximately 24-36 hours and is significantly less expensive.

Community Observations

HCG is considered essential by many TRT practitioners for maintaining testicular size and preserving fertility potential during testosterone therapy. Typical protocols use 250-500 IU two to three times per week alongside testosterone, with some clinicians preferring every-other-day dosing. The 2020 regulatory changes affecting compounded HCG availability created significant disruption for patients relying on lower-cost compounded preparations.

半衰期

~24-36 hours

复溶

Bacteriostatic water (BAC) provided with kit

存储

冻干

Refrigerate 2-8C.

复溶后

Refrigerate 2-8C. Use within 30 days.

美国法律状态

FDA-approved (Rx only)

又称作

Human Chorionic GonadotropinPregnylNovarel

常见问题

什么是 HCG?

Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone naturally produced during pregnancy that mimics luteinizing hormone (LH) activity at the Leydig cells. It is FDA-approved for the treatment of hypogonadism, cryptorchidism in pediatric patients, and as a fertility treatment to induce ovulation. In clinical practice, it is widely used alongside testosterone replacement therapy to maintain testicular function and intratesticular testosterone production.

HCG 如何起作用?

Glycoprotein hormone that mimics luteinizing hormone (LH) action. In males, stimulates Leydig cells to produce testosterone. In females, triggers ovulation and supports corpus luteum progesterone production. Maintains testicular function during exogenous hormone use.

HCG 在美国的监管状态是什么?

FDA-approved (Rx only)

HCG 的半衰期是多少?

~24-36 hours

HCG 还有哪些名称?

Human Chorionic Gonadotropin, Pregnyl, Novarel

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明